Edition:
India

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

27.87USD
8:54pm IST
Change (% chg)

$-0.41 (-1.45%)
Prev Close
$28.28
Open
$28.17
Day's High
$28.56
Day's Low
$27.67
Volume
31,795
Avg. Vol
173,904
52-wk High
$33.18
52-wk Low
$12.19

Summary

Name Age Since Current Position

Gerald Chan

67 2016 Independent Chairman of the Board

Cedric Francois

46 2016 President, Chief Executive Officer, Co-Founder, Director

Pascal Deschatelets

49 2016 Co-Founder, Chief Operating Officer

Timothy Sullivan

48 2017 Chief Financial Officer, Treasurer

Thomas Lackner

52 2019 Senior Vice President, Head of Europe

Ahmad Sadr

45 2019 Senior Vice President -Technical Operations

Nicole Perry

54 2016 Vice President - Finance

David Watson

46 2014 General Counsel, Vice President of Corporate Development

Lucia Celona

52 2019 Chief People Officer

Federico Grossi

44 2019 Chief Medical Officer

Lukas Scheibler

48 2019 Chief Innovation Officer

Adam Townsend

42 2018 Chief Commercial Officer

Sinclair Dunlop

47 2010 Independent Director

Alec Machiels

46 2009 Independent Director

Stephanie O'Brien

60 2013 Independent Director

Biographies

Name Description

Gerald Chan

Dr. Gerald Chan Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Chan co-founded Morningside in 1986. He has served as a member of the Global Advisory Council of the International Society for Stem Cell Research since 2008, the Global Advisory Council of Harvard University since 2012, the Dean’s Board of Advisors of the Harvard School of Public Health since 2011, the advisory board of the Johns Hopkins Nanjing Center since 2004 and has chaired the Innovation Advisory Committee of Wellcome Trust since 2016. Dr. Chan serves on the board of directors of Stealth BioTherapeutics Corp. and Hang Lung Group Limited. He previously served as a director of Aduro Biotech Inc. Dr. Chan received his B.S. and M.S. degrees in engineering from the University of California, Los Angeles, and his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute. Dr. Chan was elected to membership in the American Academy of Arts and Sciences in 2017. We believe that Dr. Chan is qualified to serve on our board of directors because of his extensive experience in life science investments and serving on boards of directors.

Cedric Francois

Dr. Cedric Francois M.D. Ph.D., serves as Co-Founder, President, Chief Executive Officer, Director of the Company. Dr. Francois co-founded Potentia. Dr. Francois serves on the board of directors of Liberate Medical, Inc. and Revon, which he cofounded. Dr. Francois previously served as President and Chief Executive Officer at Potentia from 2001 to 2018. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France. We believe that Dr. Francois is qualified to serve on our board of directors because of his expertise and extensive leadership experience in immunology and immune system-mediated diseases and his extensive knowledge of our company based on his role as co-founder and Chief Executive Officer.

Pascal Deschatelets

Dr. Pascal Deschatelets Ph.D. serves as Co-Founder, Chief Operating Officer of the Company. Dr. Deschatelets co-founder of our company and has served as our Chief Operating Officer since our inception in 2009. Dr. Deschatelets also co-founded Potentia and served as its Chief Operating Officer from 2001 to September 2016 and is a cofounder of Revon. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.

Timothy Sullivan

Mr. Timothy Sullivan is Chief Financial Officer, Treasurer of the Company. From January 2014 to October 2017, Mr. Sullivan served as Partner at AJU IB Investment, a venture capital firm, at which he led the firm’s investments in life sciences companies. Prior to joining AJU IB Investment, from December 2011 to January 2014, Mr. Sullivan was Managing Director, Head of Life Sciences at RBS Citizens. Mr. Sullivan was an observer on our board of directors from November 2014 until October 2017. Mr. Sullivan has previously served as a director of G1 Therapeutics, Inc. and Molecular Templates, Inc. Mr. Sullivan received his M.B.A. from the Columbia Business School and his B.A. in Biology from Harvard University.

Thomas Lackner

Mr. Thomas Lackner is Senior Vice President, Head of Europe of the Company. He has served as our Senior Vice President, Head of Europe, since January 2019. From January 2017 to December 2018 he served as Vice President, Head of European Commercial Operations at Prothena Corporation plc., a public biotechnology company. From January 2002 to December 2016 he served in various leadership roles at Biogen Corporation, a public technology company, including as Vice President and Managing Director for Germany, Austria and Switzerland from October 2010 to December 2016. Mr. Lackner holds an M.B.A. from Texas A&M University.

Ahmad Sadr

Mr. Ahmad Sadr is Senior Vice President -Technical Operations of the Company. He has served as our Senior Vice President -Technical Operations since April 2019, having served as our Vice President – Technical Operations from January 2017 to April 2019. From May 2016 to January 2017 he served as Director – Outsourced Manufacturing at Portola Pharmaceuticals, a public biotechnology company, leading critical aspects of outsourced drug substance manufacturing. From April 2015 to May 2016 he served as Vice President – Technical Operations at Vision Medicines, a private biotechnology company, and from December 2004 to April 2015 he held various leadership roles in manufacturing and supply chain at Genentech, a public biotechnology company, including as Associate Director, Manufacturing Science and Technology from June 2014 to April 2015 and Associate Director, Global External Manufacturing from February 2012 to June 2014, with responsibility for global manufacturing of development and commercial stage biologics and pharmaceutical drugs. Mr. Sadr received his B.S. in Chemical Engineering from the University of Maryland and his M.S. in Chemical Engineering at Widener University.

Nicole Perry

Ms. Nicole D. Perry is Vice President - Finance of the Company. Ms. Perry has served as our Vice President of Finance since April 2015. From April 2015 to June 2015, Ms. Perry also served as Vice President of Finance at Revon. From August 2000 to April 2015, Ms. Perry worked as an independent consultant providing services to clients primarily in the areas of financial reporting, internal control compliance and as a liaison with external accountants, bankers and legal counsel. Prior to having her consulting practice, Ms. Perry worked in the audit practices of PricewaterhouseCoopers and Deloitte. Ms. Perry is a Certified Public Accountant and received her B.B.A. in accounting, with distinction, from the University of Oklahoma.

David Watson

Mr. David O. Watson J.D., serves as General Counsel, Vice President of Corporate Development of the Company. Mr. Watson has served as our General Counsel and Vice President of Corporate Development since January 2014. From January 2014 to June 2015, Mr. Watson also served as general counsel and executive vice president of Revon. From 2006 to December 2013, Mr. Watson was a member at the law firm Frost Brown Todd LLC. Mr. Watson received his B.A. from Harvard College, his J.D. from Vanderbilt Law School and his M.A. in mathematics from the University of Kentucky.

Lucia Celona

Ms. Lucia Celona is Chief People Officer of the Company. Prior to joining Apellis, Celona worked at Bioverativ where as the Chief HR and Communications Officer she was instrumental in the formation of the company, directing matters relating to talent, organization design, culture, public affairs and employee communications. Prior to Biogen, Celona held numerous HR leadership positions in companies such as Hewlett Packard, Philips Medical Systems, including CHRO for a start-up company, Sentillion. Lucia received a Bachelor's degree in Accounting from Bentley University and has completed the Advanced HR Executive Program at the University of Michigan.

Federico Grossi

Mr. Federico Grossi M.D. Ph.D., is Chief Medical Officer of the Company. Dr. Grossi has served as our Chief Medical Officer since April 2019, having served as our Executive Vice President of Clinical Development from October 2017 until April 2019, our Vice President of Clinical Development from October 2014 to October 2017 and as our Clinical Research Director from April 2010 to June 2012. Dr. Grossi served as Executive Vice President of Potentia from October 2013 to September 2014, and as Clinical Research Director of Potentia from 2006 to April 2010. From June 2012 to October 2014, Dr. Grossi worked as an independent early stage clinical research consultant. Dr. Grossi received his M.D. from the University of Córdoba in Argentina and his Ph.D. in physiology from the University of Louisville. Following his post-graduate training in surgery, where he developed his expertise in microsurgery and composite tissue transplantation, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville.

Lukas Scheibler

Dr. Lukas Scheibler, Ph.D., is Chief Innovation Officer of the Company. He has served as our Chief Innovation Officer since April 2019, having previously served as our Executive Vice President of Research and Translational Medicine from April 2018 until April 2019. From August 2015 to December 2017, Dr. Scheibler served as head of research and development and executive vice president at Acucela Inc., a biopharmaceutical company. From June 2008 until July 2015, he served in leadership roles in research and development at Alcon Laboratories, Inc., a subsidiary of Novartis AG focused on eye care products, including as vice president, head of ideation and technology evaluation center from October 2013 to July 2015 and as vice president, global head clinical trial management from October 2011 to October 2013. Dr. Scheibler received M.Sc. in chemistry from the University of Basel in Switzerland, a Ph.D. in chemistry from the University of Lausanne in Switzerland and completed his post-doctoral training at Harvard Medical School.

Adam Townsend

Mr. Adam J. Townsend is Chief Commercial Officer of the Company. From March 2010 to October 2018 he served in a variety of leadership roles at Biogen, including as Senior Vice President of Corporate Development from March 2018 to October 2018, as Senior Vice President, Specialty Medicines and Rare Disease Group from April 2017 to March 2018, as Vice President, Asset Executive for Spinraza from May 2016 to April 2017, Vice President – Account Executive for Hemophilia from November 2015 to May 2016, and Vice President Global Marketing – Head of Multiple Sclerosis from July 2013 to November 2015. Mr. Townsend received his medical biochemistry degree from Royal Holloway, University of London.

Sinclair Dunlop

Mr. Sinclair Dunlop is Independent Director of the Company. Mr. Dunlop is a co-founder of venture capital fund Epidarex Capital and has served as the Managing Partner since July 2010. Since 2005, Mr. Dunlop has served as the Managing Partner of venture capital fund Masa Life Science Ventures, LP. Mr. Dunlop currently serves on the board of directors of several private companies. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also received an M.A. with Honors in political economy from the University of Glasgow and an M.A. in international relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. We believe that Mr. Dunlop is qualified to serve on our board of directors because of his extensive investment and business experience.

Alec Machiels

Mr. Alec Machiels, J.D., is Independent Director of the Company. Mr. Machiels is a co-founder of our company and has served as a member of our board of directors since September 2009. Since 2006, Mr. Machiels has served as a Partner at Pegasus Capital Advisors, L.P., a private equity firm that he joined in 2002. Mr. Machiels co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company, the assets of which we purchased in September 2015, and served as its Chief Executive Officer from 2001 to 2002. Mr. Machiels serves on the board of directors of Creative Realities Inc. and the board of directors of several private companies, including Revon Systems, Inc., or Revon, a private healthcare software company, which he cofounded. Mr. Machiels previously served on the board of directors of Molycorp, Inc. He started his career as a financial analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman, Sachs & Co. in New York from July 1996 until June 1999. Mr. Machiels received an M.B.A. from Harvard Business School in 2001. Mr. Machiels also received a license in law from KU Leuven Law School in Belgium and a masters in international economics from Konstanz University in Germany. We believe that Mr. Machiels is qualified to serve on our board of directors because of his strong background in financial management and investment in businesses and his experience serving on the boards of both public and private companies.

Stephanie O'Brien

Ms. Stephanie Monaghan O'Brien J.D. serves as Independent Director of the Company. Ms. O’Brien has served as a member of our board of directors since July 2013. Ms. O’Brien has been a member of the investment team at Morningside, a private investment group with venture, private equity and property investments, since 1997. She has served as a director of Aduro Biotech Inc. since 2011, and as a director of numerous private nonclinical and clinical-stage companies developing drugs across a broad spectrum of therapeutic focus, including oncology and immunotherapy, and has extensive experience providing operational and management oversight to venture-backed technology companies. Prior to joining Morningside, Ms. O’Brien spent nine years as a corporate lawyer with Hale and Dorr in its Boston and Washington, D.C. offices, working primarily on public offerings, venture capital finances and start-up companies. She previously worked at Chase Manhattan Bank, working in international portfolio analysis. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law. We believe that Ms. O’Brien is qualified to serve on our board of directors because of her strong background working with biotechnology companies and her extensive experience serving on the boards of both public and private companies.